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Commentary 
Keeping an Open Mind: Challenges and Mysteries in Cancer 
Cell Biology Research 
 
—Yusuf Ebrahim  
Cancer arises after a series of mutations or other alterations allows cells to bypass their normal 
growth checkpoints and divide freely in the body. The body aims to prevent tumors from forming by 
protecting the integrity of its cells’ DNA. One protein, p53, is so vital in this role that it is often 
referred to as the “guardian of the genome.” In fact, more than 
half of all human cancers are associated with malfunctions that 
disrupt p53 function (1). 
In a normal cell, p53 is activated during the growth cycle and, if 
the cell has substantial mutations in its DNA, p53 journeys 
from the cell’s cytoplasm to its nucleus to trigger apoptosis 
(programmed cell death). Since normal p53 prevents tumors 
by halting their spread, abnormalities in p53 might permit a 
cell to become cancerous. In some of the cancerous cells I 
studied with Dr. Walker, the seemingly unrelated protein 
mortalin, which binds to p53, is overexpressed. This keeps p53 
from entering the nucleus, and allows cancerous cells to 
survive and divide (2). My research goal has been to 
investigate this interaction, known as the “p53-mortalin 
complex,” in patient-derived and other samples of human 
cancer cells. 
I received a Summer Undergraduate Research Fellowship (SURF) in 
2016 to work in Professor Chuck Walker’s cell biology lab, where I had been involved since 2014. I 
worked under the guidance of Dr. Walker and alongside other colleagues in the lab. My work during 
that time focused on culturing cancer cells and investigating p53 within them. The various surprises I 
experienced while working on my SURF project taught me that research won’t always be as clear-cut 
as one might expect. I learned the importance of keeping an open mind and considering the 
possibility of obstacles and unexpected outcomes in order to make sense of conflicting results. 
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 Project and Challenges 
Two chemical agents used in our lab, MKT-077 and withanone, have the potential to disrupt the p53-
mortalin complex by binding to mortalin. This means that they might be able to free p53 and allow it 
to enter the nucleus to kill the cancer cells (2, 3). Because MKT-077 and withanone target the very 
mechanism that allowed the cancer to form in the first place, they should have the ability to 
discriminate between cancerous cells and healthy cells. This is in contrast to many chemotherapies in 
use today, which target any actively dividing cells and often cause damage to healthy parts of the 
body, promoting side effects such as hair loss or increased risk of infection. Withanone is an extract 
of the plant ashwagandha, which has been used in traditional Indian herbal medicine for many years. 
Although it has not been tested extensively with regard to the p53-mortalin complex, evidence 
suggests that withanone should be effective in cases where the complex is present (3). 
My project had two objectives. First, I sought to confirm the presence of the p53-mortalin complex in 
the cells I was planning to use. Second, I tried to disrupt the complex using MKT-077 and withanone 
and determine the effectiveness of these agents in allowing p53 to move to the nucleus and trigger 
apoptosis. I planned to designate groups of cells as untreated, MKT-treated, or withanone-treated. 
For each group, I chose a series of analytical techniques that could pinpoint p53 in the cell (to see 
whether it was stuck in the cytoplasm or already in the nucleus) and determine the levels of cell 
death by apoptosis. 
Initially I planned to perform this experiment on samples of cancer cells derived directly from acute 
myeloid leukemia (AML) patients. Results derived from patient samples can be more valuable than 
those derived from established cell cultures available from the American Type Culture Collection 
(ATCC), a library of cell lines. AML cells from patient samples are more like the cells that would be 
treated in a real cancer patient, because they haven’t been growing in flasks for too long. They also 
come from a variety of patients rather than only one, so they provide more widely applicable results 
regarding the effects of the chemical agents. However, these patient samples are limited in number. 
We realized our supply was low, so we would have little room for error in our experiments. Dr. 
Walker and I decided at the start of the summer to first run the experiment with a neuroblastoma cell 
line (called IMR-32), in order to make sure that our techniques and materials worked properly before 
moving to the patient samples. 
Cell lines, like IMR-32, are also derived from cancer patients, but they are grown in flasks for long 
periods, which could cause them to become different over time. IMR-32 cells were derived from a 
child who had neuroblastoma in 1967. While cells from culture may have changed from their original 
source, they can be grown indefinitely, so if we needed to repeat part of the experiment, we could 
simply prepare a new flask. In addition, because all IMR-32 cells were derived from the same patient 
many years ago, they are roughly uniform and the results should show that the p53-mortalin complex 
exists in either all of them or none of them, making our results easier to interpret. By changing the 
sample cells, I learned that I had to be flexible and willing to deviate from the original design of the 
experiment. The proposal I wrote for my project was theoretical and didn’t consider the specific 
 resources of the lab or the needs of the overall research project; when that information was brought 
to light, we had to adapt and make some tweaks to the experiment. 
At the beginning of the summer, I had trouble starting up a cell line from our lab’s vials of frozen cells. 
I tried a few times to thaw these IMR cells, but initially they did not survive. Sometimes the cells 
would give us false hope by surviving for a day or two before failing. Under the microscope, the cells 
would start off looking healthy—round and firmly adhered to the bottom of the flask. But within a 
few days, most of the cells would be floating and fragmented. 
I was using vials that we’d frozen down ourselves in the past. We ordered a fresh vial of IMR cells 
from the ATCC, a “library” that stores cells that are close to the original source of the line. This fresh 
vial was successful, and I kept a culture of IMR cells going through the summer. We think that our 
original vials weren’t working due to an incident that left the liquid nitrogen tank (where the cells 
were stored) nearly empty the preceding fall, and due to a possible error made when the cells were 
being frozen down. This experience led me through a sequence of troubleshooting: I initially 
questioned the technique I was using to thaw the cells, then the culture medium we were feeding to 
the cells, and finally the frozen vials themselves. After seeing that what I was doing wasn’t working, I 
realized that I had to make a change each time rather than repeat the same procedure. 
Starting the Treatments 
When I had the cells growing successfully, I started treating them with withanone to observe its 
effects, and I met my next obstacle. After the first treatment, I noticed under the microscope that the 
cancer cells looked as happy as ever; subsequent tests showed no significant difference in the levels 
of apoptosis, or cell death, between the withanone-treated cells and the untreated cells. Since the 
treatment seemed ineffective, my first thought was to question the vial of withanone. After 
inspecting it more closely, I discovered that it had expired. We ordered a new vial of withanone and 
repeated the treatments, but even after increasing the treatment concentration and duration to the 
maximum we had planned, the withanone-treated cells and the untreated cells appeared the same. 
The withanone was just not working. This result confused me; prior knowledge told us that 
withanone was supposed to disrupt the p53-mortalin complex in cells that have it (3). So if the 
withanone was not working, and we were performing the experiment correctly, it might mean that, 
contrary to our previous suspicions, the IMR cells don’t really have the p53-mortalin complex.  
Regardless, I didn’t think more of the matter and carried on. Next, I used a technique called 
immunocytochemistry to stain p53 in the IMR cells, and I used a microscope to observe the position 
of p53. Even in the untreated cells, the centers of the cells lit up under the microscope after the stain, 
which would indicate that most of the p53 was located in the nuclei of the IMR cells rather than in 
their cytoplasm (Figure 1). At the same time, other members of the lab had run a number of 
immunoblots, which can detect the presence of p53 in a solution of proteins, on separate solutions 
containing the cytoplasm and nuclei of the IMR cells. These blots showed that there was a lot of p53 
in the nuclei of the IMR cells and a relatively small amount of p53 in their cytoplasm. Since mortalin is 
 generally only found in the cytoplasm, this 
would further imply that the IMR cells didn’t 
have the p53-mortalin complex.  
The evidence suggesting that the IMR cells 
might not have the p53-mortalin complex 
was throwing me off, because, despite 
seeming to be self-consistent, it contradicted 
not only some literature we’d read, but also 
my own past findings from the IMR cells (4). 
However, I think that my past results were 
not as comprehensive as those during my 
summer work. Since I was facing some 
conflicting evidence about whether or not the 
p53-mortalin complex was in the IMR cells, I 
needed to do some further testing to find out 
what was true. 
Next Steps 
Because our research focuses on the p53-mortalin complex, the finding that this complex might not 
be present in the IMR cells—if true—would mean that the IMR cells won’t be relevant to our next 
research steps. However, I believe that even a negative result—the lack of something—is important, 
because we could not have known it otherwise. Due to the earlier setbacks with starting the cells up 
and repeating the withanone treatments, 
we didn’t have a chance to test the MKT on 
the IMR cells during the summer. 
Nevertheless, we gained a lot more 
experience with and knowledge about the 
experiments and analyses we were 
running.  
Our next step will be to run similar tests on 
the AML patient samples. I’m excited to 
investigate the patient samples, because 
they are so different to work with, but I am 
also interested at looking further at what’s 
going on in the IMR cells. In December 
2016, I repeated the immunocytochemistry 
for the IMR cells with a modified staining 
procedure; this showed p53 in the 
cytoplasm of the IMR cells (Figure 2). I used 
a more definitive staining procedure again 
in February 2017, which also showed p53 in 
Figure 1. IMR-32 cells stained for p53, viewed under 
fluorescent light. The glowing regions represent the 
position of p53 in the cells. The centers of the cells are 
lighting up more than their outer edges; if the stain was 
performed correctly, this can be used to demonstrate 
that p53 is located in the nucleus of IMR-32 cells. 
Figure 2. IMR-32 cells stained for p53, viewed under normal 
light. The brown spots represent the position of p53 in the 
cells. The brown regions form a ring around the outer edges 
of most of the cells; this would contradict previous findings 
and show that p53 is located in the cytoplasm of IMR-32 
cells. 
 the cytoplasm of the IMR cells (Figure 3). My next step, therefore, will be to investigate whether it is 
mortalin that is responsible for keeping p53 in the cytoplasm, by using a technique called co-
immunoprecipitation, which can identify whether proteins are bound together. After that, depending 






Final Thoughts and Lessons 
I learned a number of valuable lessons by performing this research, in addition to new lab methods. I 
worked mostly independently on my project, with guidance from Dr. Walker, which allowed me to 
make choices such as restructuring parts of the experiment based on the results I was seeing. Most of 
all, I learned that it is important to actively keep an open mind, especially in science. It took me a 
while to understand that withanone was not effective against the IMR cells, despite changing the 
experiment repeatedly—new withanone, longer incubation times, higher concentrations—with the 
assumption that I was running some part incorrectly because I wasn’t seeing the result I expected. It 
was good that I repeated and changed the experiment to rule out other possibilities, but when I 
accepted that the withanone just wasn’t working, I started thinking about why that might be and 
changed my previous ideas about the IMR cells. In other words, I never expected to get unexpected 
results. This lesson will be important in my goals moving forward—I hope to become a doctor, and 
the ability to question myself and my previous ideas will be equally valuable in that setting. Because 
of the support of my lab mates and my mentor, my undergraduate research in Dr. Walker’s lab has 
been my favorite experience at the University of New Hampshire. I eagerly look forward to continuing 
my work in the lab.  
I would like to thank Dr. Walker for always instilling curiosity in me, guiding me in my research, and 
providing me with invaluable support in my journey. I would also like to thank the Hamel Center for 
Undergraduate Research for giving me the opportunity to conduct the research and making it all 
possible. Finally, I would like to thank all the students, former students, and staff I’ve worked with in 
the lab, who were always helping me in my project and providing me with company: Bria Frehner, 
Jasmina Cesko, Brianna Looney, Seth McNutt, Andrew Morin, Harrison LeFlem, Professor Anne 
Böttger, and Dylan Laprise. 
Figure 3. IMR-32 cells stained for p53, viewed under fluorescent light with two different filters. The 
blue regions in the image on the left represent the cells’ nuclei, whereas the green regions in the 
center image represent the position of p53 in the cells. The image on the right is the result of 
merging the left and center images. This shows that p53 is located in the cytoplasm of IMR-32 cells, 
because most of the green regions (p53) are concentrated outside the blue regions (nucleus). 
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